Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C19 CYP2C9 CYP2C18	1.59e-06	4	148	3	GO:0071614
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.74e-06	14	148	4	GO:0008401
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C19 CYP2C8 CYP2C9	2.17e-05	8	148	3	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C19 CYP2C8 CYP2C9	2.17e-05	8	148	3	GO:0034875
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.74e-05	24	148	4	GO:0008392
GeneOntologyMolecularFunction	iron ion binding	CYP2C19 CYP2C8 CYP2C9 CYP2C18 ALKBH8 FECH HAAO ALOX5	3.38e-05	166	148	8	GO:0005506
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2C19 CYP2C8 CYP2C9 CYP2C18	4.45e-05	27	148	4	GO:0008391
GeneOntologyMolecularFunction	(R)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0052741
GeneOntologyMolecularFunction	(S)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0018675
GeneOntologyMolecularFunction	(S)-limonene 7-monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0018676
GeneOntologyMolecularFunction	limonene monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0019113
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP2C19 CYP2C8 CYP2C9	6.30e-05	11	148	3	GO:0101020
GeneOntologyMolecularFunction	aromatase activity	CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.27e-04	35	148	4	GO:0070330
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C19 CYP2C8 CYP2C9	1.70e-04	15	148	3	GO:0016725
GeneOntologyMolecularFunction	arachidonate 11,12-epoxygenase activity	CYP2C19 CYP2C9	3.24e-04	4	148	2	GO:0008405
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	CYP2C19 CYP2C8 CYP2C9 CYP2C18	4.74e-04	49	148	4	GO:0016712
GeneOntologyMolecularFunction	cytoskeletal protein binding	LIN7C MYO1E EPB41L4B MYO9B CD2AP STX1A KCNA2 PPP5C PTPRN XIRP2 CLTC VPS41 ANTXR1 AFDN SSH2 PLEC EPB41L1 PACSIN2 HTT	5.01e-04	1099	148	19	GO:0008092
GeneOntologyMolecularFunction	fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	5.38e-04	5	148	2	GO:0120502
GeneOntologyMolecularFunction	long-chain fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	5.38e-04	5	148	2	GO:0120319
GeneOntologyMolecularFunction	arachidonate 14,15-epoxygenase activity	CYP2C19 CYP2C9	5.38e-04	5	148	2	GO:0008404
GeneOntologyMolecularFunction	GTPase activator activity	RASA1 MYO9B PREX2 ARHGAP1 TBC1D1 RAB3GAP2 PREX1 PLXNB1	1.15e-03	279	148	8	GO:0005096
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	RASA1 TRIO MYO9B NUCB1 PREX2 PREB ARHGAP1 TBC1D1 RAB3GAP2 PREX1 PLXNB1	1.43e-03	507	148	11	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	RASA1 TRIO MYO9B NUCB1 PREX2 PREB ARHGAP1 TBC1D1 RAB3GAP2 PREX1 PLXNB1	1.43e-03	507	148	11	GO:0030695
GeneOntologyMolecularFunction	actin filament binding	MYO1E MYO9B CD2AP XIRP2 ANTXR1 AFDN PLEC	1.54e-03	227	148	7	GO:0051015
GeneOntologyMolecularFunction	monooxygenase activity	CYP2C19 CYP2C8 CYP2C9 CYP2C18 AKR1D1	1.67e-03	115	148	5	GO:0004497
GeneOntologyMolecularFunction	steroid hydroxylase activity	CYP2C19 CYP2C8 CYP2C9	2.02e-03	34	148	3	GO:0008395
GeneOntologyBiologicalProcess	epoxygenase P450 pathway	CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.64e-05	22	147	4	GO:0019373
GeneOntologyBiologicalProcess	actin filament-based process	RASA1 MYO1E PDGFRA EPB41L4B MYO9B CD2AP PEAK3 RYR2 HMCN1 XIRP2 PDXP ANTXR1 PRKG1 SSH2 PLEC PREX1 EPB41L1 PACSIN2 SCN3B	2.69e-05	912	147	19	GO:0030029
GeneOntologyCellularComponent	axon	TANC2 SLC4A8 PDGFRA NTRK3 CD2AP GRM1 STX1B ADCY9 STX1A KCNA2 SACS PTPRN AFDN PLEC PREX1 DYNC1H1 HTT	1.96e-04	891	148	17	GO:0030424
GeneOntologyCellularComponent	synaptic membrane	SLC4A8 LIN7C NTRK3 GRM1 STX1B STX1A KCNA2 PTPRA NETO2 CLTC AFDN EPB41L1 HTT	2.65e-04	583	148	13	GO:0097060
GeneOntologyCellularComponent	matrilin complex	MATN1 MATN3	2.96e-04	4	148	2	GO:0120216
Domain	VWFA	COL6A6 MATN1 MATN3 ITGAE HMCN1 ANTXR1 ITIH6	4.12e-06	82	149	7	PS50234
Domain	VWA	COL6A6 MATN1 MATN3 ITGAE HMCN1 ANTXR1 ITIH6	4.84e-06	84	149	7	SM00327
Domain	VWA	COL6A6 MATN1 MATN3 ITGAE ANTXR1 ITIH6	5.45e-06	56	149	6	PF00092
Domain	VWF_A	COL6A6 MATN1 MATN3 ITGAE HMCN1 ANTXR1 ITIH6	1.44e-05	99	149	7	IPR002035
Domain	-	COL6A6 MATN1 MATN3 HMCN1 ANTXR1 ITIH6	2.76e-05	74	149	6	3.40.50.410
Domain	STX1A/1B	STX1B STX1A	6.32e-05	2	149	2	IPR028669
Domain	CLH	CLTC VPS41	1.89e-04	3	149	2	SM00299
Domain	Matrilin_ccoil	MATN1 MATN3	3.75e-04	4	149	2	SM01279
Domain	-	MATN1 MATN3	3.75e-04	4	149	2	1.20.5.30
Domain	Matrilin_ccoil	MATN1 MATN3	3.75e-04	4	149	2	PF10393
Domain	Matrilin_coiled-coil_trimer	MATN1 MATN3	3.75e-04	4	149	2	IPR019466
Domain	Cyt_P450_E_grp-I	CYP2C19 CYP2C8 CYP2C9 CYP2C18	4.50e-04	45	149	4	IPR002401
Pathway	KEGG_ARACHIDONIC_ACID_METABOLISM	CYP2C19 CYP2C8 CYP2C9 CYP2C18 HPGDS ALOX5	9.46e-06	58	120	6	M5410
Pathway	REACTOME_ARACHIDONIC_ACID_METABOLISM	CYP2C19 CYP2C8 CYP2C9 MAPKAPK2 HPGDS ALOX5	1.05e-05	59	120	6	M27140
Pathway	REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET	CYP2C19 CYP2C8 CYP2C9	3.27e-05	8	120	3	M27135
Pathway	REACTOME_BIOSYNTHESIS_OF_MARESINS	CYP2C8 CYP2C9 ALOX5	3.27e-05	8	120	3	M27891
Pathway	REACTOME_XENOBIOTICS	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.90e-05	23	120	4	M5372
Pathway	REACTOME_SYNTHESIS_OF_16_20_HYDROXYEICOSATETRAENOIC_ACIDS_HETE	CYP2C19 CYP2C8 CYP2C9	4.87e-05	9	120	3	M27143
Pathway	REACTOME_CYP2E1_REACTIONS	CYP2C19 CYP2C8 CYP2C9	9.44e-05	11	120	3	M27130
Pathway	KEGG_LINOLEIC_ACID_METABOLISM	CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.01e-04	29	120	4	M2920
Pathway	REACTOME_BIOSYNTHESIS_OF_MARESINS	CYP2C19 CYP2C8 ALOX5	1.25e-04	12	120	3	MM15616
Pathway	WP_OCTADECANOID_FORMATION_FROM_LINOLEIC_ACID	CYP2C19 CYP2C8 CYP2C9	1.25e-04	12	120	3	M48064
Pathway	REACTOME_ARACHIDONIC_ACID_METABOLISM	CYP2C19 CYP2C8 MAPKAPK2 HPGDS ALOX5	1.67e-04	61	120	5	MM14861
Pathway	WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES	CYP2C19 CYP2C9 CYP2C18	2.04e-04	14	120	3	MM15842
Pathway	PID_RAC1_REG_PATHWAY	TRIO PREX2 ARHGAP1 PREX1	2.95e-04	38	120	4	M241
Pathway	REACTOME_RHOJ_GTPASE_CYCLE	TRIO ARHGAP1 PREX1	3.11e-04	16	120	3	MM15605
Pathway	KEGG_DRUG_METABOLISM_CYTOCHROME_P450	CYP2C19 CYP2C8 CYP2C9 CYP2C18 MAOA	3.65e-04	72	120	5	M9257
Pathway	REACTOME_ECM_PROTEOGLYCANS	COL6A6 MATN1 MATN3 LAMA4 TNR	4.69e-04	76	120	5	M27219
Pubmed	Biochemistry and molecular biology of the human CYP2C subfamily.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.32e-10	4	150	4	7704034
Pubmed	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.32e-10	4	150	4	19706858
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.32e-10	4	150	4	2009263
Pubmed	Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.32e-10	4	150	4	21798861
Pubmed	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.32e-10	4	150	4	23755828
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	MYO1E TRIO IFT172 NUCB1 ZNFX1 PREPL BFSP1 SEPTIN2 ARHGAP1 STX1A PTPRA PPP5C SACS DROSHA NEMF CLTC AFDN PLEC PC PREX1 DYNC1H1 PCM1	3.72e-08	1285	150	22	35914814
Pubmed	Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.	ELOA SCO2 CYP2C9 PDGFRA COQ2 PREPL PREX2 CCNA2 XYLT2 ARHGAP1 NBAS ALKBH8 PTPRA RAB3GAP2 FECH CLTC VPS41 FGF3 SSH2 PC PCM1 HTT	6.53e-08	1327	150	22	32694731
Pubmed	The human CYP2C locus: a prototype for intergenic and exon repetition splicing events.	CYP2C8 CYP2C9 CYP2C18	7.86e-08	3	150	3	10704292
Pubmed	CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	35134542
Pubmed	Distribution of CYP2C polymorphisms in an Amerindian population of Brazil.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	21977947
Pubmed	Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	23118231
Pubmed	Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	28687336
Pubmed	A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	8530044
Pubmed	Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	21173785
Pubmed	Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities.	CYP2C19 CYP2C9 CYP2C18	7.86e-08	3	150	3	15102943
Pubmed	Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	24430292
Pubmed	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	20665013
Pubmed	Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	27803446
Pubmed	Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.	CYP2C19 CYP2C8 CYP2C9	7.86e-08	3	150	3	19954515
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily.	CYP2C19 CYP2C9 CYP2C18	7.86e-08	3	150	3	8095407
Pubmed	Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.	CYP2C19 CYP2C8 CYP2C9	3.14e-07	4	150	3	28990182
Pubmed	Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.	CYP2C19 CYP2C8 CYP2C9	3.14e-07	4	150	3	16025294
Pubmed	A high-throughput approach for measuring temporal changes in the interactome.	MYO1E CD2AP NUCB1 OSGEP NCAPH SEPTIN2 TGM2 NUDT5 DPP9 PPP5C NANS AHNAK RAB3GAP2 GNAI2 PSME3 PLEC ARIH1 CLUH DYNC1H1 EPB41L1 PACSIN2 HTT	3.16e-07	1455	150	22	22863883
Pubmed	Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.22e-07	14	150	4	19290787
Pubmed	Association of warfarin dose with genes involved in its action and metabolism.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	5.81e-07	16	150	4	17048007
Pubmed	Pluripotency factors regulate definitive endoderm specification through eomesodermin.	PDGFRA SOX17 FZD8 PCDH19	5.81e-07	16	150	4	21245162
Pubmed	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.	CYP2C19 CYP2C8 CYP2C9	7.81e-07	5	150	3	19415824
Pubmed	Prevalence of CYP450 gene variations in patients with type 2 diabetes.	CYP2C19 CYP2C8 CYP2C9	7.81e-07	5	150	3	20857895
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	TANC2 CAMKK1 TRIO PDGFRA NTRK3 CD2AP CDC14A TBC1D1 AHNAK RAB3GAP2 AFDN SSH2 PLEC PC EPB41L1 PCM1	1.08e-06	861	150	16	36931259
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	TDRD15 EPB41L4B LCN8 NCAPH ADCY9 RYR2 ARHGAP1 AHNAK CLTC ADAMTS16 AFDN PSME3 PC DYNC1H1 PCM1	1.50e-06	777	150	15	35844135
Pubmed	Molecular genetics of the human cytochrome P450 monooxygenase superfamily.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.53e-06	20	150	4	9890157
Pubmed	Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.	CYP2C19 CYP2C8 CYP2C9	1.56e-06	6	150	3	17635176
Pubmed	A genome-wide association study of acenocoumarol maintenance dosage.	CYP2C19 CYP2C9 CYP2C18	1.56e-06	6	150	3	19578179
Pubmed	The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.	TRIO MYO9B LARS2 ARHGAP1 SACS AHNAK CLTC PLEC DYNC1H1 PCM1	1.97e-06	332	150	10	37433992
Pubmed	Systems analysis of RhoGEF and RhoGAP regulatory proteins reveals spatially organized RAC1 signalling from integrin adhesions.	TANC2 LIN7C TRIO RBM33 RBL1 CD2AP PREPL PREX2 SEPTIN2 ARHGAP1 AHNAK PSME3 PLEC CPVL PREX1 PACSIN2	2.41e-06	916	150	16	32203420
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	TANC2 CAMKK1 ADCY9 KCNA2 SACS RAB3GAP2 PLEC EPB41L1 PCM1 HTT	2.92e-06	347	150	10	17114649
Pubmed	LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.	TRIO MYO9B TM9SF4 ZNFX1 NBAS AHNAK CLTC PLEC	2.93e-06	202	150	8	33005030
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	ELOA VRK2 TRIO CDC14A ADCY9 ARHGAP1 PTPRA NUDT5 PPP5C PTPRN AHNAK FECH CLTC SSH2 PC CPVL EPB41L1	3.13e-06	1049	150	17	27880917
Pubmed	Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling.	TRIO NTRK3 GRM1 SACS AHNAK CLTC TNR DYNC1H1 EPB41L1	3.97e-06	281	150	9	28706196
Pubmed	The Absence of Sensory Axon Bifurcation Affects Nociception and Termination Fields of Afferents in the Spinal Cord.	NTRK3 CLTC PRKG1	4.33e-06	8	150	3	29472841
Pubmed	Genetic and genomic analysis of a fat mass trait with complex inheritance reveals marked sex specificity.	VRK2 CYP2C19 CYP2C9	4.33e-06	8	150	3	16462940
Pubmed	Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer.	CD2AP NCAPH NUDT5 PSME3 DYNC1H1	4.88e-06	57	150	5	38223760
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	CD2AP NCAPH NUDT5 AHNAK RAB3GAP2 CLTC AFDN PSME3 PC DYNC1H1 PCM1 HTT	5.10e-06	549	150	12	38280479
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	ERCC4 RNF31 EPB41L4B RBL1 ZNFX1 PREB TGM2 DROSHA NEMF ANTXR1 AFDN EPB41L1 PLXNB1	5.32e-06	650	150	13	38777146
Pubmed	EB1-binding-myomegalin protein complex promotes centrosomal microtubules functions.	CD2AP AHNAK CLTC PSME3 PLEC	8.02e-06	63	150	5	29162697
Pubmed	Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	8.35e-06	30	150	4	20529763
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	TANC2 SLC4A8 ACADS TRIO ZNFX1 STX1B RYR2 PREB STX1A PPP5C RAB3GAP2 CLTC AFDN PLEC PC EPB41L1 PCM1	9.20e-06	1139	150	17	36417873
Pubmed	Let-7 microRNA-dependent control of leukotriene signaling regulates the transition of hematopoietic niche in mice.	SOX17 DROSHA ALOX5	9.23e-06	10	150	3	28743859
Pubmed	Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.	CYP2C19 CYP2C8 CYP2C9	9.23e-06	10	150	3	20602612
Pubmed	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.	CYP2C19 CYP2C8 CYP2C9	9.23e-06	10	150	3	19651758
Pubmed	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome.	TRIO LAMA4 FSD2 OSGEP PREPL PPP5C XIRP2 DROSHA CLTC PSME3 PLEC	1.14e-05	497	150	11	23414517
Pubmed	Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.	CYP2C19 CYP2C8 CYP2C9	1.26e-05	11	150	3	15469410
Pubmed	Endogenous nonecotropic proviruses mapped with oligonucleotide probes from the long terminal repeat region.	CYP2C19 CYP2C9 PTPRA	1.26e-05	11	150	3	8075500
Pubmed	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.	CYP2C19 CYP2C8 CYP2C9	1.26e-05	11	150	3	15039299
Pubmed	Systematically defining selective autophagy receptor-specific cargo using autophagosome content profiling.	VRK2 LIN7C TRIO TM9SF4 NUCB1 OSGEP LARS2 RING1 ARHGAP1 AHNAK NEMF CLTC ANTXR1 GNAI2 ARIH1 CLUH DYNC1H1 PCM1	1.32e-05	1297	150	18	33545068
Pubmed	Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia.	CYP2C19 CYP2C8 CYP2C9 ERCC4 CYP2C18 PDGFRA ITGAE	1.35e-05	179	150	7	19074885
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	TANC2 MYO1E TRIO EPB41L4B ZNFX1 GRM1 STX1B SEPTIN2 PTPRA SACS CLTC AFDN SSH2 PLEC PC TNR DYNC1H1 EPB41L1 PCM1	1.38e-05	1431	150	19	37142655
Pubmed	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.	CYP2C19 CYP2C8 CYP2C18	1.68e-05	12	150	3	15319333
Pubmed	Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform.	CYP2C8 CYP2C9	1.85e-05	2	150	2	7574697
Pubmed	5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases.	MAPKAPK2 ALOX5	1.85e-05	2	150	2	10779545
Pubmed	Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative.	CYP2C8 CYP2C9	1.85e-05	2	150	2	30562214
Pubmed	Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.	CYP2C8 CYP2C9	1.85e-05	2	150	2	26122864
Pubmed	Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.	CYP2C8 CYP2C9	1.85e-05	2	150	2	12435384
Pubmed	Important amino acid residues that confer CYP2C19 selective activity to CYP2C9.	CYP2C19 CYP2C9	1.85e-05	2	150	2	18511451
Pubmed	HPC-1/syntaxin 1A and syntaxin 1B play distinct roles in neuronal survival.	STX1B STX1A	1.85e-05	2	150	2	24666284
Pubmed	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.	CYP2C8 CYP2C9	1.85e-05	2	150	2	18694831
Pubmed	Developmental expression of human hepatic CYP2C9 and CYP2C19.	CYP2C19 CYP2C9	1.85e-05	2	150	2	14634042
Pubmed	Semaphorin 4D/Plexin-B1 stimulates PTEN activity through R-Ras GTPase-activating protein activity, inducing growth cone collapse in hippocampal neurons.	RASA1 PLXNB1	1.85e-05	2	150	2	20610402
Pubmed	CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract.	CYP2C19 CYP2C9	1.85e-05	2	150	2	10908295
Pubmed	Titration of Syntaxin1 in mammalian synapses reveals multiple roles in vesicle docking, priming, and release probability.	STX1B STX1A	1.85e-05	2	150	2	24133272
Pubmed	Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme.	CYP2C19 CYP2C9	1.85e-05	2	150	2	1847130
Pubmed	The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.	CYP2C19 CYP2C8	1.85e-05	2	150	2	28513222
Pubmed	Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes.	CYP2C19 CYP2C9	1.85e-05	2	150	2	17599801
Pubmed	Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model.	CYP2C19 CYP2C18	1.85e-05	2	150	2	19038035
Pubmed	Control of cerebellar long-term potentiation by P-Rex-family guanine-nucleotide exchange factors and phosphoinositide 3-kinase.	PREX2 PREX1	1.85e-05	2	150	2	20694145
Pubmed	Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.	TGM2 HTT	1.85e-05	2	150	2	24955833
Pubmed	Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.	CYP2C19 CYP2C9	1.85e-05	2	150	2	15385837
Pubmed	Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin.	TGM2 HTT	1.85e-05	2	150	2	17403029
Pubmed	[Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].	CYP2C19 CYP2C9	1.85e-05	2	150	2	25518510
Pubmed	Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.	CYP2C9 CYP2C18	1.85e-05	2	150	2	8333835
Pubmed	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.	CYP2C8 CYP2C9	1.85e-05	2	150	2	16372821
Pubmed	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	CYP2C19 CYP2C9	1.85e-05	2	150	2	15842554
Pubmed	Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.	CYP2C19 CYP2C9	1.85e-05	2	150	2	19136640
Pubmed	Elevated Type 1 Metabotropic Glutamate Receptor Availability in a Mouse Model of Huntington's Disease: a Longitudinal PET Study.	GRM1 HTT	1.85e-05	2	150	2	31912442
Pubmed	Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage.	CYP2C19 CYP2C9	1.85e-05	2	150	2	35748067
Pubmed	Linkage disequilibrium between the CYP2C1917 and CYP2C82 alleles in populations of African descent.	CYP2C19 CYP2C8	1.85e-05	2	150	2	20890775
Pubmed	A conserved role for Syntaxin-1 in pre- and post-commissural midline axonal guidance in fly, chick, and mouse.	STX1B STX1A	1.85e-05	2	150	2	29912942
Pubmed	Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development.	CYP2C19 CYP2C9	1.85e-05	2	150	2	32587777
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.	CYP2C19 CYP2C9	1.85e-05	2	150	2	17201743
Pubmed	CYP2C9 (2&3) and CYP2C19 (2&3) polymorphisms among children with nonlesional epilepsy: a single-center study.	CYP2C19 CYP2C9	1.85e-05	2	150	2	32683556
Pubmed	Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.	CYP2C8 CYP2C9	1.85e-05	2	150	2	18548238
Pubmed	Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.	CYP2C19 CYP2C9	1.85e-05	2	150	2	15855721
Pubmed	The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.	CYP2C19 CYP2C9	1.85e-05	2	150	2	19847408
Pubmed	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.	CYP2C19 CYP2C9	1.85e-05	2	150	2	17504998
Pubmed	Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors.	CYP2C19 CYP2C9	1.85e-05	2	150	2	24519941
Pubmed	Abnormal collagen fibrils in cartilage of matrilin-1/matrilin-3-deficient mice.	MATN1 MATN3	1.85e-05	2	150	2	17502381
Pubmed	Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice.	CYP2C19 CYP2C9	1.85e-05	2	150	2	14623888
Pubmed	Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction.	CYP2C8 CYP2C9	1.85e-05	2	150	2	14646690
Pubmed	Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.	CYP2C8 CYP2C18	1.85e-05	2	150	2	10487415
Pubmed	Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.	CYP2C8 CYP2C9	1.85e-05	2	150	2	19480553
Interaction	CYP2C18 interactions	VRK2 CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.46e-06	27	149	5	int:CYP2C18
Interaction	CYP2C19 interactions	CYP2C19 CYP2C9 CYP2C18	3.92e-06	5	149	3	int:CYP2C19
Cytoband	20q13.13	SLC9A8 ZNFX1 PREX1	1.58e-04	32	150	3	20q13.13
Cytoband	10q24	CYP2C19 CYP2C9 CYP2C18	2.07e-04	35	150	3	10q24
Cytoband	Ensembl 112 genes in cytogenetic band chr10q23	CYP2C19 CYP2C8 CYP2C9 CYP2C18 LIPJ	4.72e-04	195	150	5	chr10q23
Cytoband	3p24.1	ZCWPW2 NEK10	5.72e-04	11	150	2	3p24.1
Cytoband	10q11.2	PRKG1 ALOX5	9.40e-04	14	150	2	10q11.2
GeneFamily	Cytochrome P450 family 2	CYP2C19 CYP2C8 CYP2C9 CYP2C18	4.37e-05	35	102	4	1001
GeneFamily	Tudor domain containing	TDRD15 TDRD7 UHRF2	1.18e-03	37	102	3	780
GeneFamily	UPF1 like RNA helicases	ZNFX1 MOV10L1	1.68e-03	11	102	2	1169
GeneFamily	PDZ domain containing	LIN7C PREX2 AHNAK AFDN PREX1	1.70e-03	152	102	5	1220
Coexpression	HALLMARK_MITOTIC_SPINDLE	RASA1 MYO1E TRIO MYO9B CD2AP SSH2 PREX1 DYNC1H1 PCM1	2.31e-06	199	150	9	M5893
CoexpressionAtlas	dev lower uro neuro_e15.5_PelvicGanglion_Sox10_k-means-cluster#4_top-relative-expression-ranked_500	NTRK3 RYR2 NBAS HMCN1 TNR	9.11e-06	41	147	5	gudmap_dev lower uro neuro_e15.5_PelvicGanglion_Sox10_k4_500
CoexpressionAtlas	dev lower uro neuro_e14.5_BladdPelvicGanglion_Sox10_k-means-cluster#3_top-relative-expression-ranked_500	TANC2 NTRK3 TNR	3.76e-05	10	147	3	gudmap_dev lower uro neuro_e14.5_BladdPelvicGanglion_Sox10_k3_500
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL15A1 NTRK3 LAMA4 PREX2 RYR2 HMCN1 PLXDC2 ANTXR1 PAPPA PRKG1	1.64e-09	200	150	10	58b38f9a484ee94191091a0659ed62ebed2d4a14
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D231\|Adult / Lineage, Cell type, age group and donor	COL15A1 COL6A6 PDGFRA LAMA4 RYR2 TGM2 HMCN1 ANTXR1 PRKG1	2.01e-08	193	150	9	ef2f456c094e6e3c6ee81e0668c953cb8d0e1c0a
ToppCell	Control-Fibroblasts-Intermediate_pathological_FB\|Control / group, cell type (main and fine annotations)	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 PLXDC2 ANTXR1 PAPPA PRKG1	2.10e-08	194	150	9	03a269f75a481ea54aea8e6444605db8d6df493d
ToppCell	COVID-19-Fibroblasts-Intermediate_pathological_FB\|COVID-19 / group, cell type (main and fine annotations)	COL15A1 PDGFRA LAMA4 RYR2 HMCN1 ADAMTS16 ANTXR1 PAPPA PRKG1	2.40e-08	197	150	9	f1c8936986123a3151140c374fcd62d6705c530b
ToppCell	COVID-19-lung-Fibroblast\|lung / Disease (COVID-19 only), tissue and cell type	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 PLXDC2 ANTXR1 PAPPA PRKG1	2.51e-08	198	150	9	df3de77216f5c5d6141ec44d01c56b942f611838
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL15A1 COL6A6 PDGFRA LAMA4 PREX2 TGM2 HMCN1 PLXDC2 ANTXR1	2.73e-08	200	150	9	3dd022e974fec7013ba18f333da63f58fbf2dd7c
ToppCell	Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	NTRK3 RYR2 NT5C1A TGM2 HMCN1 KLHL30 PAPPA PRKG1	1.40e-07	174	150	8	015d3742d3d79a57413a333f00ef2d380a9848dd
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Endothelial-blood_vessel_EC-Fetal_arterial_EC\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CACNA1F COL15A1 SOX17 PREX2 NETO2 AFDN GNAI2 PREX1	2.24e-07	185	150	8	602536a3308a848f106adcb0a83530997440c8f4
ToppCell	Control-Fibroblasts-Other_FB\|Control / group, cell type (main and fine annotations)	COL15A1 PDGFRA LAMA4 RYR2 HMCN1 PLXDC2 ANTXR1 PRKG1	2.44e-07	187	150	8	bd3739c4a52aa1ba5deffd778e113a9800f7e158
ToppCell	TCGA-Breast-Primary_Tumor-Breast_Carcinoma-Infiltrating_Ductal_Carcinoma-6\|TCGA-Breast / Sample_Type by Project: Shred V9	MATN3 PTGFRN ARHGAP1 HMCN1 PLXDC2 ADAMTS16 ANTXR1 PRKG1	2.44e-07	187	150	8	a96495803ba13fcfadd1d83b3cf5774f3fed0a20
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A6 LAMA4 ADCY9 RYR2 PLXDC2 ANTXR1 PAPPA PRKG1	2.64e-07	189	150	8	2a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCell	Control-Fibroblasts\|Control / group, cell type (main and fine annotations)	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 PLXDC2 ANTXR1 PRKG1	2.75e-07	190	150	8	3a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell	facs-Heart-LV-24m-Mesenchymal-ventricular_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FSD2 GRM1 RYR2 NT5C1A PTPRN XIRP2 KLHL30 MOV10L1	2.86e-07	191	150	8	543da1197c7e62f2c9cbd4a51414bbaaa6d1a92f
ToppCell	facs-Heart-LV-24m-Mesenchymal-ventricular_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FSD2 GRM1 RYR2 NT5C1A PTPRN XIRP2 KLHL30 MOV10L1	2.86e-07	191	150	8	9d7d680da3979e256191b534ebd14c5383e0cf93
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TANC2 RASA1 TRIO MYO9B PLXDC2 PCNX1 SSH2 ARIH1	3.10e-07	193	150	8	779276e775cb2492e8dd36436295a536084a6415
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL15A1 PDGFRA NTRK3 LAMA4 HMCN1 ADAMTS16 ANTXR1 PRKG1	3.10e-07	193	150	8	5de87fc94a6e58899ef4124cf4887ed3ff96163a
ToppCell	IPF-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	COL15A1 ZCWPW2 COL6A6 LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	3.48e-07	196	150	8	7fc9894ceb79dab9f0495acc84e2d6d0d1c69bb7
ToppCell	IPF-Stromal-Myofibroblast\|IPF / Disease state, Lineage and Cell class	COL15A1 ZCWPW2 COL6A6 LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	3.48e-07	196	150	8	2d0a48e49b3b37bb66e33e74c52915911e1f8a74
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MATN3 SOX17 LAMA4 PREX2 SEPTIN2 TGM2 HMCN1 PRKG1	3.48e-07	196	150	8	ed818de15f84f7f28bd06fd69d7876710da232a0
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL6A6 LAMA4 PREX2 HMCN1 PLXDC2 MOV10L1 ANTXR1 PRKG1	3.62e-07	197	150	8	0dd71e399f253787fa546a7e90c5373180b89ffd
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 PLXDC2 ANTXR1 PRKG1	3.76e-07	198	150	8	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	Tracheal-10x5prime-Stromal-Fibroblastic-Fibro_peribronchial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	COL15A1 COL6A6 PDGFRA NTRK3 HMCN1 ANTXR1 PAPPA PRKG1	4.06e-07	200	150	8	8ab0051544ea32eb8b3f7f8ba7582deaf8bf26c0
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL15A1 PDGFRA LAMA4 PREX2 HMCN1 PLXDC2 ANTXR1 PRKG1	4.06e-07	200	150	8	b4ccffdd79526c85e5273d27b668dbddcddba1ee
ToppCell	Bronchus_Control_(B.)-Stromal-TX-Fibroblasts-1\|Bronchus_Control_(B.) / Sample group, Lineage and Cell type	COL15A1 PDGFRA NTRK3 LAMA4 PREX2 RYR2 PAPPA PRKG1	4.06e-07	200	150	8	16a3685c41194a0a4a772e4eee372160263480e0
ToppCell	facs-Liver-Hepatocytes-24m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F FSD2 PLXDC2 HPGDS ALOX5 EPB41L1 SCN3B	1.68e-06	168	150	7	04e168fe1d6f5f9e3d3bf9d7c13e800e3594868a
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-ASMC\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL15A1 NTRK3 LAMA4 RYR2 SACS ANTXR1 PRKG1	2.04e-06	173	150	7	cb6389536195443633adb06e5f1b7483530773d1
ToppCell	droplet-Mammary_Gland-nan-3m-Endothelial-nan\|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SCRN3 CHST14 SOX17 FZD8 TGM2 UHRF2 SCN3B	2.04e-06	173	150	7	fbc8ed566ea36c39c258dd6b3823c82f5d6eb17f
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Rectal_Adenocarcinoma-7\|TCGA-Colorectal / Sample_Type by Project: Shred V9	SLC9A8 TM9SF4 LAMA4 PROSER1 HMCN1 ANTXR1 EPB41L1	2.46e-06	178	150	7	edc76b8f15056ec1c9a1c61a048b6331a92592d6
ToppCell	RA-13._Vascular_Smooth_Muscle\|RA / Chamber and Cluster_Paper	MYO1E NTRK3 LAMA4 TBC1D1 ANTXR1 PRKG1 PACSIN2	2.96e-06	183	150	7	818fd886e0188091310825f9145fa53328f2c979
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F ZAN GRM1 RYR2 HMCN1 XIRP2 ADAMTS16	3.07e-06	184	150	7	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F ZAN GRM1 RYR2 HMCN1 XIRP2 ADAMTS16	3.07e-06	184	150	7	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F ZAN GRM1 RYR2 HMCN1 XIRP2 ADAMTS16	3.07e-06	184	150	7	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	10x3'2.3-week_17-19-Endothelial-stroma-proliferating_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	COL15A1 MYO1E SOX17 LAMA4 PREX2 BFSP1 AFDN	3.29e-06	186	150	7	a844d4f79e0ad5d6c60a4488ffd8f4f21b7eed04
ToppCell	Control-Fibroblasts-Alveolar_FB\|Control / group, cell type (main and fine annotations)	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 PLXDC2 PRKG1	3.41e-06	187	150	7	92d468dde81125d51daf7abd4703741abe1ab91c
ToppCell	facs-Heart-Unknown-3m-Mesenchymal-ventricular_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FSD2 GRM1 RYR2 PTPRN XIRP2 KLHL30 MOV10L1	3.54e-06	188	150	7	4db566f3f708e66730aa9e16f4d73d91dc534177
ToppCell	facs-Heart-Unknown-3m-Mesenchymal-ventricular_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FSD2 GRM1 RYR2 PTPRN XIRP2 KLHL30 MOV10L1	3.54e-06	188	150	7	6704b92991ad8c0a910e9f36cd33d00bd26dcb8f
ToppCell	PND10\|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RASA1 PREX2 HMCN1 AHNAK ANTXR1 AFDN SCN3B	3.79e-06	190	150	7	d67e2814047c8df2ae4b7bc8be9539f5df6ecef2
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A6 LAMA4 RYR2 PLXDC2 ANTXR1 PAPPA PRKG1	3.92e-06	191	150	7	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	NTRK3 LAMA4 PREX2 RYR2 AHNAK ADAMTS16 PRKG1	3.92e-06	191	150	7	fa380a8752de158974b2ae5e741573439719cc0d
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	3.92e-06	191	150	7	6688cee34beee4f151ac17fccbc9c26a9aad72e1
ToppCell	nucseq-Mesenchymal-Myocytic-Myocytic_2-SCMF\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL15A1 PDGFRA LAMA4 HMCN1 ADAMTS16 ANTXR1 PRKG1	4.06e-06	192	150	7	67e845e513e76e820f55e2f0d15eb16f2944d05c
ToppCell	nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.06e-06	192	150	7	99ce9e3c4c50cf64ebb62145f2b5420efa0db309
ToppCell	LPS_only-Stromal_mesenchymal\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL6A6 LAMA4 RYR2 PLXDC2 ANTXR1 PAPPA PRKG1	4.06e-06	192	150	7	162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158
ToppCell	343B-Lymphocytic-ILC-ILC-1\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	SCRN3 PROSER1 TGM2 DPP9 RAB3GAP2 CLUH HTT	4.06e-06	192	150	7	445985fe1bcd33e4f0a1704b27988fbfc9334538
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	COL6A6 LAMA4 RYR2 TGM2 HMCN1 PLXDC2 PRKG1	4.06e-06	192	150	7	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	COVID-19-Fibroblasts-Other_FB\|COVID-19 / group, cell type (main and fine annotations)	PDGFRA RYR2 HMCN1 PLXDC2 ANTXR1 PAPPA PRKG1	4.20e-06	193	150	7	e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-fibroblastic\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PDGFRA NTRK3 LAMA4 PLXDC2 ADAMTS16 PAPPA PRKG1	4.20e-06	193	150	7	68089ba4123e2f9bea9aae0023a844b5a57bfc0e
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	LAMA4 RYR2 TGM2 HMCN1 PLXDC2 ANTXR1 PRKG1	4.35e-06	194	150	7	011e14d9ed1393275f892060e7708ffadcd0767f
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	COL6A6 NTRK3 LAMA4 PREX2 HMCN1 PLXDC2 PRKG1	4.35e-06	194	150	7	71d3c7448b1734de54187f902f65649f9283bd4c
ToppCell	Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	COL6A6 LAMA4 RYR2 TGM2 HMCN1 PLXDC2 PRKG1	4.35e-06	194	150	7	35f132cc38ac133be01834ed0946188aa0757eb4
ToppCell	Control-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	ZCWPW2 COL6A6 LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.35e-06	194	150	7	3c2266772c5b56e8e02a461e5193e29588028ee9
ToppCell	Control-Stromal-Myofibroblast\|Control / Disease state, Lineage and Cell class	ZCWPW2 COL6A6 LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.50e-06	195	150	7	ffcf76cd72e43d8cf1058a49c76e0956065038bc
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	COL6A6 PDGFRA LAMA4 RYR2 TGM2 HMCN1 PRKG1	4.50e-06	195	150	7	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	COPD-Stromal-Myofibroblast\|COPD / Disease state, Lineage and Cell class	ZCWPW2 COL6A6 LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.65e-06	196	150	7	af206bb5bbb8b604a6212acd79878bcc3d326cec
ToppCell	facs-Bladder-nan-3m\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LARS2 TGM2 PTPRA PLXDC2 AHNAK CLTC DYNC1H1	4.65e-06	196	150	7	44f5b1b474399c9316729155f2ea95a82ca66e30
ToppCell	facs-Bladder-nan-3m-Epithelial\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	LARS2 TGM2 PTPRA PLXDC2 AHNAK CLTC DYNC1H1	4.65e-06	196	150	7	c0e90d964baa2eb4fbd18a52379ccec5d3bf59a8
ToppCell	nucseq-Mesenchymal-Fibroblastic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.65e-06	196	150	7	7d8505dac15fa59935ccf592afc54b04c4c6554f
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_immature\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MAOA MATN3 SOX17 LAMA4 PREX2 TGM2 HMCN1	4.81e-06	197	150	7	62c0a90869431e582bb7bb329e0b0cc59123d3d1
ToppCell	COPD-Stromal-Myofibroblast\|World / Disease state, Lineage and Cell class	ZCWPW2 COL6A6 LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.81e-06	197	150	7	d51f484b4e01ac64233950d0b97fa88825ea1dbb
ToppCell	COVID-19-lung-Macrophage_VCANhi_FCN1hi\|lung / Disease (COVID-19 only), tissue and cell type	MYO9B PLXDC2 DDX60L SSH2 CPVL PREX1 ALOX5	4.81e-06	197	150	7	a0f8a992282a6d64890f5574c7c9741fcb38dadd
ToppCell	10x_3'_v2v3-Non-neoplastic-Endothelial-Endothelial_immature-Tip-like\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MAOA MATN3 SOX17 LAMA4 PREX2 TGM2 HMCN1	4.81e-06	197	150	7	16f0eb047df9d702518f82ee99c6e7dc1350b2fb
ToppCell	COVID-19-Fibroblasts\|COVID-19 / group, cell type (main and fine annotations)	PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PAPPA PRKG1	4.81e-06	197	150	7	fb847f2277609c31fffcdf49517243ce0684facf
ToppCell	IPF-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	TANC2 COL15A1 COL6A6 RYR2 HMCN1 PLXDC2 ANTXR1	4.81e-06	197	150	7	f304d42fc4936fe20996e07c8dccc698a6e5e5ef
ToppCell	5'-GW_trimst-2-SmallIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL15A1 LAMA4 TGM2 PLXDC2 ANTXR1 PRKG1 TNR	4.97e-06	198	150	7	09be07ebfc3e49c3858e9b74605b69cf4fc28b56
ToppCell	tumor_Lung-Fibroblasts-Myofibroblasts\|tumor_Lung / Location, Cell class and cell subclass	COL15A1 PDGFRA MATN3 LAMA4 ADAMTS16 ANTXR1 PRKG1	4.97e-06	198	150	7	31f9181dab689aabe9c6182c2ef7de65ba3f0ff6
ToppCell	Adult-Mesenchymal\|Adult / Lineage, Cell type, age group and donor	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.97e-06	198	150	7	26e55b409db2a1637c95fae7c54b0abea1ef550c
ToppCell	nucseq-Mesenchymal\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	4.97e-06	198	150	7	8f52243ca8b9ba68a75ae411506a3a6de258eb97
ToppCell	5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	EPB41L4B NEK10 IFT172 SPEF2 DNAH12 AHNAK PCM1	4.97e-06	198	150	7	d0ecace1fad24ce50b0935036fabb07e6c9e372d
ToppCell	Fetal_29-31_weeks-Mesenchymal\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	COL6A6 LAMA4 RYR2 HMCN1 PLXDC2 ANTXR1 PRKG1	4.97e-06	198	150	7	21cf4d81386761d09d0f6829c01c198e5524176d
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	COL6A6 PDGFRA LAMA4 RYR2 TGM2 PLXDC2 PRKG1	5.14e-06	199	150	7	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	Bronchial-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL6A6 LAMA4 RYR2 HMCN1 PLXDC2 PAPPA PRKG1	5.31e-06	200	150	7	389cc775c8419d90fb77cd794376d2160a7bf44e
ToppCell	Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	COL6A6 PDGFRA LAMA4 RYR2 HMCN1 ANTXR1 PRKG1	5.31e-06	200	150	7	8c62f05c6042f24287a73fbdf80ff4a56f7ff403
ToppCell	tumor_Lymph_Node_/_Brain-Fibroblasts-Myofibroblasts\|tumor_Lymph_Node_/_Brain / Location, Cell class and cell subclass	COL15A1 PDGFRA MATN3 LAMA4 HMCN1 ANTXR1 PRKG1	5.31e-06	200	150	7	ca777a7d001848f6d01c613ff2bda7e4f3e20521
ToppCell	Biopsy_IPF-Mesenchymal-Myofibroblasts\|Biopsy_IPF / Sample group, Lineage and Cell type	COL15A1 COL6A6 PDGFRA LAMA4 HMCN1 ANTXR1 PRKG1	5.31e-06	200	150	7	c2c6f687c49ba790174b27c7b8b084af30b34c86
ToppCell	facs-Heart-LV-18m-Mesenchymal-atrial_cardiomyocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RBM33 GPR141 IL18RAP CCNA2 FECH PSME3	1.24e-05	151	150	6	5893a51585a65f1902cf85124a5ed9f02b4eb82a
ToppCell	facs-Heart-LV-18m-Mesenchymal-atrial_myocyte\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RBM33 GPR141 IL18RAP CCNA2 FECH PSME3	1.24e-05	151	150	6	771224e0d6fccfa4225b3adccd7bc22a89a40793
ToppCell	Children_(3_yrs)-Mesenchymal-vascular_smooth_muscle_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NTRK3 RYR2 HMCN1 TBC1D1 PAPPA PRKG1	2.05e-05	165	150	6	8a82e20c9b1156bb4bbc16f7785abb04458d671b
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TANC2 RASA1 CDC14A SACS AHNAK PCNX1	2.20e-05	167	150	6	83969c36ac44b96afc9aa09400a99fa2b487f7ff
ToppCell	facs-Liver-Hepatocytes-24m-Myeloid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F FSD2 PLXDC2 HPGDS ALOX5 EPB41L1	2.27e-05	168	150	6	4ae9e9d93bcd6f4d5815e57fd5afa7a3398a0ec1
ToppCell	facs-Liver-Hepatocytes-24m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F FSD2 PLXDC2 HPGDS ALOX5 EPB41L1	2.35e-05	169	150	6	454b92b9b67299a64278c010db033ca5b9d217a0
ToppCell	LV-13._Vascular_Smooth_Muscle\|LV / Chamber and Cluster_Paper	MYO1E NTRK3 TBC1D1 ANTXR1 PRKG1 PACSIN2	2.51e-05	171	150	6	e99ecae66530d1ae09330cee408c8f3950b87e67
ToppCell	droplet-Kidney-nan-3m-Epithelial-Pecam____kidney_capillary_endothelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL15A1 CHST14 LAMA4 PREX2 SACS PRKG1	2.59e-05	172	150	6	073a503dc922e3e3ac3528e249b0f8b74402110b
ToppCell	facs-Large_Intestine-Distal-24m-Epithelial-Brush_cell_of_epithelium_proper_of_large_intestine\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1F COL15A1 CAMKK1 XIRP2 HPGDS ALOX5	2.68e-05	173	150	6	f0eb48c1283bdde313bb75f6ffc0d2626922d24b
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CYP2C9 GRM1 NCAPH SNX32 CLUH PLXNB1	2.77e-05	174	150	6	207aa0118633cbe9a65839bbb1bb3ba9f8118ad2
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL15A1 RYR2 HMCN1 XIRP2 AHNAK PCM1	2.95e-05	176	150	6	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	facs-Heart-LV-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL15A1 PDGFRA IFT172 LAMA4 PLXDC2 ANTXR1	2.95e-05	176	150	6	fee4e0f32aaf77294040c7af6c1f503571750d43
ToppCell	facs-Heart-LV-18m-Mesenchymal-fibroblast_of_cardiac_tissue\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	COL15A1 PDGFRA IFT172 LAMA4 PLXDC2 ANTXR1	2.95e-05	176	150	6	f25251abd4ef9fb077a978f9f9f658af58e4e0d2
ToppCell	TCGA-Ovary-Primary_Tumor\|TCGA-Ovary / Sample_Type by Project: Shred V9	PDGFRA CHST14 NUCB1 PROSER1 EPB41L1	2.98e-05	106	150	5	14f548be39cec604fbdae0382cbf434fa4049840
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma\|TCGA-Ovary / Sample_Type by Project: Shred V9	PDGFRA CHST14 NUCB1 PROSER1 EPB41L1	2.98e-05	106	150	5	939b80950d39cdc7149a05fdfb64c8810064cdb1
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma\|TCGA-Ovary / Sample_Type by Project: Shred V9	PDGFRA CHST14 NUCB1 PROSER1 EPB41L1	2.98e-05	106	150	5	e9e1b55f32b3d5b9eeec94a997912e5c21c1fb48
ToppCell	356C-Fibroblasts-Fibroblast-C_(Myofibroblast)-\|356C / Donor, Lineage, Cell class and subclass (all cells)	COL15A1 COL6A6 PDGFRA LAMA4 RYR2 PRKG1	3.05e-05	177	150	6	cdfd2f0ee2f692271b1525e414b0f645cdadb1f6
ToppCell	356C-Fibroblasts-Fibroblast-C_(Myofibroblast)\|356C / Donor, Lineage, Cell class and subclass (all cells)	COL15A1 COL6A6 PDGFRA LAMA4 RYR2 PRKG1	3.05e-05	177	150	6	db222faaecbe5600da39277243c4e7e764eb63c9
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL15A1 HMCN1 PTPRN ADAMTS16 ANTXR1 PAPPA	3.35e-05	180	150	6	935c091bbcd6d10b81dc4731779e5bd98205c99f
ToppCell	5'-Airway_Nasal-Mesenchymal\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL15A1 HMCN1 PTPRN ADAMTS16 ANTXR1 PAPPA	3.35e-05	180	150	6	3dd384b7f3d9582b8fec9fe05100e466e6218b76
ToppCell	Control-Fibroblasts-Airway_smooth_muscle\|Control / group, cell type (main and fine annotations)	COL15A1 NTRK3 LAMA4 RYR2 ANTXR1 PRKG1	3.35e-05	180	150	6	d0de12749ef0f51f0931c6e7b9b99966bdbc3ec1
ToppCell	5'-GW_trimst-2-LargeIntestine-Hematopoietic-Myeloid-CLC+_Mast_cell\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SLC4A8 CAMKK1 GPR141 PEAK3 HPGDS ALOX5	3.45e-05	181	150	6	338c7362d258a87f1a6b1a65376f5394d4b2b4b2
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	COL6A6 LAMA4 PREX2 RYR2 HMCN1 PRKG1	3.45e-05	181	150	6	9ede19228ba5c0668a9c06c915510b95585216ef
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL15A1 HMCN1 PTPRN ADAMTS16 ANTXR1 PAPPA	3.67e-05	183	150	6	803376f5260de83c48d4f7301278d078a32b3e6e
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL15A1 HMCN1 PTPRN ADAMTS16 ANTXR1 PAPPA	3.67e-05	183	150	6	6d98973098c6d20c5305bce6a83a549a7d8dbfba
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	COL15A1 HMCN1 PTPRN ADAMTS16 ANTXR1 PAPPA	3.67e-05	183	150	6	cc7f5a17b40e8d901885174922e5fa8877643071
Computational	Cytochrome P450.	CYP2C19 CYP2C8 CYP2C9 CYP2C18	6.31e-06	14	99	4	MODULE_106
Drug	4',5-dihydroxydiclofenac	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.62e-08	6	149	4	CID003052567
Drug	3'-hydroxydiclofenac	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.62e-08	6	149	4	CID000112230
Drug	5-bromotryptamine	CYP2C19 CYP2C8 CYP2C9 MAOA	1.21e-07	8	149	4	ctd:C040997
Drug	5-chlorotryptamine	CYP2C19 CYP2C8 CYP2C9 MAOA	2.16e-07	9	149	4	ctd:C529169
Drug	Dexamethasone acetate [1177-87-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	ACADS CDC14A PREX2 RYR2 ZNF419 ARHGAP1 TGM2 PTPRA PCNX1 PCM1	7.55e-07	198	149	10	2242_DN
Drug	Probucol [23288-49-5]; Up 200; 7.8uM; MCF7; HT_HG-U133A	SCRN3 MAOA ACADS MATN3 GRM1 SLC3A1 PPP5C AHNAK ALOX5 PLXNB1	7.55e-07	198	149	10	3223_UP
Drug	5-hydroxydiclofenac	CYP2C19 CYP2C8 CYP2C9 CYP2C18	8.37e-07	12	149	4	CID003052566
Drug	2'-(glutathion-S-yl)-deschlorodiclofenac	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.27e-06	15	149	4	ctd:C586542
Drug	3-Pz	CYP2C9 MAPKAPK2 KCNA2	2.72e-06	5	149	3	CID000644328
Drug	bufuralol	CYP2C19 CYP2C8 CYP2C9	2.72e-06	5	149	3	ctd:C010831
Drug	Azamulinum	CYP2C19 CYP2C8 CYP2C9 CYP2C18	5.02e-06	18	149	4	CID003086060
Drug	D 703	CYP2C19 CYP2C8 CYP2C9 CYP2C18	5.02e-06	18	149	4	CID000054088
Drug	oxygen	SCO2 CYP2C19 CYP2C8 CYP2C9 CYP2C18 MAOA ACADS AKR1D1 COQ2 STX1A KCNA2 CLTC HAAO ALOX5	5.37e-06	499	149	14	CID000000977
Drug	4,4'-cyclohexylidenebisphenol	CYP2C19 CYP2C8 CYP2C9	5.41e-06	6	149	3	ctd:C570106
Drug	AC1O5Z5L	CYP2C19 CYP2C8 CYP2C9	5.41e-06	6	149	3	CID006443527
Drug	Naftifine hydrochloride [65473-14-5]; Up 200; 12.4uM; HL60; HT_HG-U133A	MYO1E MYO9B MAPKAPK2 CDC14A PREX2 ADCY9 ARHGAP1 ANTXR1 AFDN	6.22e-06	197	149	9	2974_UP
Drug	hydroxytolbutamide	CYP2C19 CYP2C8 CYP2C9 CYP2C18	6.33e-06	19	149	4	CID000003656
Drug	racemethorphan	CYP2C19 CYP2C8 CYP2C9 CYP2C18 MAOA GRM1 SCN3B	6.74e-06	107	149	7	CID000003008
Drug	3C etc	CYP2C19 CYP2C8 CYP2C9 CYP2C18	7.87e-06	20	149	4	CID000164045
Drug	16-O-demethylaconitine	CYP2C19 CYP2C8 CYP2C9	9.43e-06	7	149	3	ctd:C486136
Drug	5-fluorotryptamine	CYP2C19 CYP2C8 CYP2C9	9.43e-06	7	149	3	ctd:C034536
Drug	6-Fluoro-6-desoxyoxymorphone	CYP2C19 CYP2C8 CYP2C9	9.43e-06	7	149	3	CID005486899
Drug	AC1L21VM	CYP2C19 CYP2C8 CYP2C9 CPVL	9.67e-06	21	149	4	CID000039524
Drug	C20H32O4	CYP2C19 CYP2C8 CYP2C9 CYP2C18 RBL1 ALOX5	1.24e-05	78	149	6	CID000001440
Drug	3-hydroxymethylantipyrine	CYP2C8 CYP2C9 CYP2C18 PSME3	1.42e-05	23	149	4	CID000123963
Drug	13-hydroxyeicosatetraenoic acid	CYP2C19 CYP2C8 CYP2C9	1.50e-05	8	149	3	CID006439499
Drug	5-fluoro-alpha-methyltryptamine	CYP2C19 CYP2C9 MAOA	1.50e-05	8	149	3	ctd:C051101
Drug	5-methyltryptamine	CYP2C19 CYP2C9 MAOA	1.50e-05	8	149	3	ctd:C027552
Drug	11-HODE	CYP2C19 CYP2C8 CYP2C9	1.50e-05	8	149	3	CID006438497
Drug	1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid	CYP2C19 CYP2C8 CYP2C9	1.50e-05	8	149	3	ctd:C585955
Drug	7-methyltryptamine	CYP2C19 CYP2C9 MAOA	1.50e-05	8	149	3	ctd:C036696
Drug	deferoxamine	CYP2C19 CYP2C8 CYP2C9 CYP2C18 CDC14A TFAP2B BFSP1 CCNA2 FECH PACSIN2 HTT	1.68e-05	343	149	11	CID000002973
Drug	N-nitrosomethylethylamine	CYP2C19 CYP2C8 CYP2C9 SLC3A1	1.69e-05	24	149	4	CID000025418
Drug	Tranylcypromine	CYP2C19 CYP2C8 CYP2C9 MAOA	2.00e-05	25	149	4	ctd:D014191
Drug	Tolbutamide	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.00e-05	25	149	4	ctd:D014044
Drug	AC1L44DC	CYP2C19 CYP2C8 CYP2C9 PLEC	2.00e-05	25	149	4	CID000150456
Drug	K-K-K	CYP2C19 CYP2C8 CYP2C9 CYP2C18 PDXP PSME3 PRKG1 ALOX5	2.06e-05	175	149	8	CID000003823
Drug	4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide	CYP2C19 CYP2C9 CYP2C18	2.24e-05	9	149	3	ctd:C545880
Drug	Acenocoumarol	CYP2C19 CYP2C9 CYP2C18	2.24e-05	9	149	3	ctd:D000074
Drug	Tryptamines	CYP2C19 CYP2C8 CYP2C9	2.24e-05	9	149	3	ctd:D014363
Drug	3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate	CYP2C19 CYP2C8 CYP2C9	2.24e-05	9	149	3	ctd:C109602
Drug	5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid	CYP2C19 CYP2C8 CYP2C9	2.24e-05	9	149	3	ctd:C000588958
Drug	11-HETE	CYP2C19 CYP2C8 CYP2C9 ALOX5	2.35e-05	26	149	4	CID000001406
Drug	1,4-naphthoquinone	CYP2C19 CYP2C8 CYP2C9 CYP2C18	2.35e-05	26	149	4	ctd:C035342
Drug	carbamazepine	CYP2C19 CYP2C8 CYP2C9 MAOA ADCY9 NT5C1A PC SCN3B	2.42e-05	179	149	8	CID000002554
Drug	almotriptan	CYP2C19 CYP2C8 MAOA	3.19e-05	10	149	3	ctd:C409045
Drug	norketobemidone	CYP2C19 CYP2C8 CYP2C9	3.19e-05	10	149	3	CID000161154
Drug	sitaxsentan	CYP2C19 CYP2C8 CYP2C9	3.19e-05	10	149	3	ctd:C106276
Drug	orphenadrine	CYP2C19 CYP2C8 CYP2C9 PSME3 SCN3B	3.28e-05	56	149	5	CID000004601
Drug	rifampicin	CYP2C19 CYP2C8 CYP2C9 CYP2C18 CD2AP TGM2 TBC1D1 PLEC PACSIN2 HTT	3.50e-05	306	149	10	CID005381226
Drug	(hydrochloride)	CYP2C19 CYP2C8 CYP2C9 CYP2C18	3.68e-05	29	149	4	CID000004923
Drug	norselegiline	CYP2C19 CYP2C8 CYP2C9 MAOA	3.68e-05	29	149	4	CID000185859
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A	ACADS TRIO PDGFRA MYO9B CDC14A TGM2 KAT8 PCM1	4.14e-05	193	149	8	5922_UP
Drug	dibenzylfluorescein	CYP2C19 CYP2C9	4.25e-05	2	149	2	ctd:C558664
Drug	NSC-685705	MAPKAPK2 KCNA2	4.25e-05	2	149	2	CID000389483
Drug	Agehoustin B	MAPKAPK2 KCNA2	4.25e-05	2	149	2	CID000389484
Drug	Moclobemide	CYP2C19 MAOA	4.25e-05	2	149	2	ctd:D020912
Drug	camelliaside A	RBL1 ALOX5	4.25e-05	2	149	2	CID005748475
Drug	fenvalerate	CYP2C19 CYP2C8 CYP2C9 MAOA PTGFRN SCN3B	4.30e-05	97	149	6	ctd:C017690
Drug	Haloperidol metabolite I	CYP2C19 CYP2C8 CYP2C9	4.36e-05	11	149	3	CID000038282
Drug	trans-1,2-dihydro-1,2-naphthalenediol	CYP2C19 CYP2C8 CYP2C9	4.36e-05	11	149	3	ctd:C507866
Drug	Ursolic acid [77-52-1]; Down 200; 8.8uM; PC3; HT_HG-U133A	MAOA TRIO MYO9B NCAPH FZD8 PTPRA FECH PCNX1	4.46e-05	195	149	8	5825_DN
Drug	propafenone	CYP2C19 CYP2C9 CYP2C18 KCNA2 CPVL SCN3B	4.56e-05	98	149	6	CID000004932
Drug	Betahistine mesylate [54856-23-4]; Down 200; 17.2uM; MCF7; HT_HG-U133A	TRIO MAPKAPK2 XYLT2 ARHGAP1 NBAS STX1A PLEC ARIH1	4.62e-05	196	149	8	4956_DN
Drug	Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; MCF7; HT_HG-U133A	SLC9A8 ERCC4 MYO1E CDC14A ARHGAP1 TGM2 PTPRA PLEC	4.62e-05	196	149	8	3441_UP
Drug	Tropine [120-29-6]; Down 200; 28.4uM; HL60; HT_HG-U133A	MAOA GRM1 CDC14A SLC3A1 XYLT2 STX1A VPS41 CPVL	4.62e-05	196	149	8	6147_DN
Drug	Solasodine [126-17-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A	COL15A1 CYP2C18 MYO9B MATN1 FRMD1 ANTXR1 AFDN ALOX5	4.96e-05	198	149	8	6025_UP
Drug	Propidium iodide [25535-16-4]; Down 200; 6uM; HL60; HT_HG-U133A	ACADS MYO1E TRIO LAMA4 GRM1 RYR2 HAAO PCM1	4.96e-05	198	149	8	2541_DN
Drug	magnesium	VRK2 RASA1 MYO1E NUCB1 LAMA4 OSGEP GRM1 COQ2 ADCY9 RYR2 CCNA2 ARHGAP1 NT5C1A NUDT5 HPGDS NANS DROSHA PDXP PLEC PC ALOX5 DYNC1H1	5.22e-05	1325	149	22	CID000000888
Drug	Dehydroisoandosterone 3-acetate [853-23-6]; Down 200; 12.2uM; HL60; HT_HG-U133A	MAOA MYO1E MAPKAPK2 NUCB1 GRM1 FRMD1 AFDN PCM1	5.33e-05	200	149	8	3097_DN
Drug	BP-7,8-oxide	CYP2C19 CYP2C8 CYP2C9 CYP2C18	5.49e-05	32	149	4	CID000037455
Drug	4-(N-propionylanilino)piperidine	CYP2C19 CYP2C8 CYP2C9	5.79e-05	12	149	3	CID000259381
Drug	carveol	CYP2C19 CYP2C8 CYP2C9	5.79e-05	12	149	3	CID000007438
Drug	desethylamodiaquine	CYP2C19 CYP2C8 CYP2C9	5.79e-05	12	149	3	ctd:C047386
Drug	norclozapine	CYP2C19 CYP2C8 CYP2C9	5.79e-05	12	149	3	ctd:C058272
Drug	zafirlukast	CYP2C19 CYP2C8 CYP2C9 ALOX5	6.22e-05	33	149	4	CID000005717
Drug	Fluoxetine	CYP2C19 CYP2C8 CYP2C9 MAOA NUCB1 CCNA2 GNAI2 PRKG1 PLEC PLXNB1	6.75e-05	331	149	10	ctd:D005473
Drug	erlotinib	CYP2C19 CYP2C9 RASA1 PDGFRA CLTC FGF3 DYNC1H1	6.82e-05	153	149	7	CID000176870
Drug	AC1O5XSP	CYP2C8 CYP2C9 CYP2C18 ALOX5	7.01e-05	34	149	4	CID006442739
Drug	AC1L18GM	CYP2C19 CYP2C8 CYP2C9	7.49e-05	13	149	3	CID000000092
Drug	7-hydroxyquinoline	CYP2C19 CYP2C8 CYP2C9	7.49e-05	13	149	3	CID000011378
Drug	1'-hydroxymidazolam	CYP2C19 CYP2C8 CYP2C9	7.49e-05	13	149	3	CID000107917
Drug	clozapine N-oxide	CYP2C19 CYP2C8 CYP2C9	7.49e-05	13	149	3	CID000036727
Drug	5,6-epoxyeicosatrienoic acid	CYP2C19 CYP2C8 CYP2C9 CYP2C18 ALOX5	8.39e-05	68	149	5	CID000001778
Drug	(Z) Fluvoxamine	CYP2C19 CYP2C8 CYP2C9 CYP2C18 MAOA	9.00e-05	69	149	5	CID000003404
Drug	8(9)-EET	CYP2C19 CYP2C8 CYP2C9 CYP2C18 ALOX5	9.00e-05	69	149	5	CID000001901
Drug	propionanilide	CYP2C19 CYP2C8 CYP2C9	9.48e-05	14	149	3	CID000012107
Drug	5-MeO-DIPT	CYP2C19 CYP2C8 CYP2C9	9.48e-05	14	149	3	CID000151182
Drug	verapamil	CACNA1F CYP2C19 CYP2C8 CYP2C9 CYP2C18 ADCY9 RYR2 KCNA2 PDXP GNAI2 ALOX5 SCN3B	9.54e-05	490	149	12	CID000002520
Drug	1h1q	CYP2C19 CYP2C8 CYP2C9 CYP2C18 CCNA2	9.64e-05	70	149	5	CID000001540
Drug	4-bromophenol	CYP2C8 CYP2C9 CYP2C18 NT5C1A TBC1D1	9.64e-05	70	149	5	CID000007808
Drug	venlafaxine	CYP2C19 CYP2C8 CYP2C9 MAOA PREX2	9.64e-05	70	149	5	CID000005656
Drug	phenytoin	CACNA1F CYP2C19 CYP2C8 CYP2C9 CYP2C18 RYR2 KCNA2 SCN3B	1.00e-04	219	149	8	CID000001775
Drug	DMEs	CYP2C19 CYP2C8 CYP2C9 CYP2C18 PLEC	1.03e-04	71	149	5	CID003038361
Drug	proadifen hydrochloride	CYP2C19 CYP2C8 CYP2C9 CYP2C18 MAOA ALOX5	1.06e-04	114	149	6	CID000004910
Drug	4-hydroxymephenytoin	CYP2C19 CYP2C8 CYP2C9	1.18e-04	15	149	3	CID000119507
Drug	11,14,15-THET	CYP2C8 CYP2C9 CYP2C18 ALOX5	1.21e-04	39	149	4	CID006439531
Drug	thiotepa	CYP2C19 CYP2C8 CYP2C9 TBC1D1	1.21e-04	39	149	4	CID000005453
Drug	entadamide A	RBL1 ALOX5	1.27e-04	3	149	2	CID006439215
Drug	picoxystrobin	CYP2C19 CYP2C9	1.27e-04	3	149	2	ctd:C556557
Disease	X-21258 measurement	CYP2C19 CYP2C9 CYP2C18	1.24e-07	3	148	3	EFO_0800802
Disease	Intellectual Disability	TANC2 TRIO OSGEP PREPL CCNA2 ALKBH8 KCNA2 SACS KAT8 DYNC1H1 EPB41L1 HTT	2.87e-06	447	148	12	C3714756
Disease	Lambert-Eaton Myasthenic Syndrome	PREPL PLEC	2.50e-05	2	148	2	C0022972
Disease	Myasthenic Syndrome	PREPL PLEC	2.50e-05	2	148	2	C0549225
Disease	X-14473 measurement	CYP2C19 CYP2C18	2.50e-05	2	148	2	EFO_0021370
Disease	Cardiac arrhythmia	RYR2 GNAI2	2.50e-05	2	148	2	cv:C0003811
Disease	Genetic cardiac rhythm disease	RYR2 GNAI2	2.50e-05	2	148	2	cv:C5681782
Disease	Schizophrenia	CACNA1F VRK2 MAOA MYO9B NTRK3 GRM1 LARS2 CCNA2 ARHGAP1 TGM2 STX1A PTPRA HPGDS KAT8 PCM1	4.01e-05	883	148	15	C0036341
Disease	cyclo(leu-pro) measurement	CYP2C19 CYP2C18	7.47e-05	3	148	2	EFO_0800676
Disease	platelet-derived growth factor receptor alpha measurement	PDGFRA CFHR5	7.47e-05	3	148	2	EFO_0021844
Disease	lymphocyte count	CYP2C19 CYP2C9 ZAN ZCWPW2 RBL1 SPEF2 IL18RAP PREX2 ADCY9 PPP5C TBC1D1 AHNAK PAPPA GNAI2 DDX60L SSH2 PLEC PREX1 HTT	1.39e-04	1464	148	19	EFO_0004587
Disease	Hypotonia-Cystinuria Syndrome	PREPL SLC3A1	1.49e-04	4	148	2	C1848030
Disease	patent ductus arteriosus (is_implicated_in)	SOX17 TFAP2B	1.49e-04	4	148	2	DOID:13832 (is_implicated_in)
Disease	2p21 microdeletion syndrome	PREPL SLC3A1	1.49e-04	4	148	2	C4304537
Disease	nephrotic syndrome (implicated_via_orthology)	CD2AP COQ2 ALOX5	2.32e-04	24	148	3	DOID:1184 (implicated_via_orthology)
Disease	Familial ventricular tachycardia	RYR2 GNAI2	2.47e-04	5	148	2	C0340485
Disease	pulmonary tuberculosis	RBL1 LAMA4 SCN3B	4.11e-04	29	148	3	EFO_1000049
Disease	complex trait	TDRD15 ZAN IFT172 CFHR5 STX1B NBAS KAT8	4.54e-04	271	148	7	EFO_0010578
Disease	glycine conjugate of C10H14O2 (1) measurement	CYP2C9 CYP2C18	5.16e-04	7	148	2	EFO_0800655
Disease	peripheral neuropathy	NTRK3 XIRP2	5.16e-04	7	148	2	EFO_0003100
Disease	Huntington's disease (implicated_via_orthology)	HAAO PACSIN2 HTT	5.51e-04	32	148	3	DOID:12858 (implicated_via_orthology)
Disease	cleft lip	TANC2 FSD2 PTGFRN FRMD1 SEPTIN2 OLFM3 PRKG1	5.99e-04	284	148	7	EFO_0003959
Disease	lobe attachment	PDGFRA GRM1 PREX2 HMCN1 SACS FECH	6.39e-04	207	148	6	EFO_0007667
Disease	neurodegenerative disease (implicated_via_orthology)	SCO2 RASA1 DYNC1H1 PACSIN2 HTT	8.42e-04	145	148	5	DOID:1289 (implicated_via_orthology)
Disease	plasma clozapine-to-N-desmethylclozapine ratio measurement	CYP2C19 CYP2C18	8.79e-04	9	148	2	EFO_0600040
Disease	egg allergy measurement	ERCC4 ITIH6	8.79e-04	9	148	2	EFO_0007018
Disease	myeloid white cell count	ACADS MYO1E CDC14A PREX2 TGM2 OLFM3 PTPRA SNX32 SSH2 TNR PREX1 PLXNB1 HTT	9.10e-04	937	148	13	EFO_0007988
Disease	periodontitis	GPR141 NUDT5 TBC1D1 ANTXR1 PLEC UHRF2	9.41e-04	223	148	6	EFO_0000649
Disease	S-6-hydroxywarfarin to S-warfarin ratio measurement	CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.02e-03	88	148	4	EFO_0803332
Disease	Inherited focal segmental glomerulosclerosis	MYO1E CD2AP	1.10e-03	10	148	2	cv:CN327126
Disease	Focal segmental glomerulosclerosis	MYO1E CD2AP	1.10e-03	10	148	2	cv:C0017668
Disease	response to anticoagulant	CYP2C19 CYP2C9 CPVL	1.15e-03	41	148	3	GO_0061476
Disease	X-11308 measurement	CYP2C19 CYP2C9	1.33e-03	11	148	2	EFO_0800693
Disease	Hereditary Nephrotic Syndromes, Autosomal Dominant	MYO1E CD2AP	1.33e-03	11	148	2	cv:CN043612
Disease	Basal cell carcinoma	ERCC4 RASA1	1.33e-03	11	148	2	C0007117
Disease	campesterol measurement	PREPL SLC3A1	1.33e-03	11	148	2	EFO_0020008
Disease	S-warfarin to R-warfarin ratio measurement	CYP2C19 CYP2C8 CYP2C9 CYP2C18	1.36e-03	95	148	4	EFO_0803331
Disease	epilepsy (implicated_via_orthology)	TRIO STX1B KCNA2 PRKG1 DYNC1H1	1.42e-03	163	148	5	DOID:1826 (implicated_via_orthology)
Disease	waist circumference	TRIO GRM1 TFAP2B STX1B ADCY9 PTPRN KAT8 PREX1	1.50e-03	429	148	8	EFO_0004342
Disease	thymol sulfate measurement	CYP2C19 CYP2C9	1.60e-03	12	148	2	EFO_0021170
Disease	Huntington Disease, Late Onset	MAOA HTT	1.60e-03	12	148	2	C0393574
Disease	Akinetic-Rigid Variant of Huntington Disease	MAOA HTT	1.60e-03	12	148	2	C0751207
Disease	Juvenile Huntington Disease	MAOA HTT	1.60e-03	12	148	2	C0751208
Disease	Male sterility	CDC14A TDRD7 DROSHA	1.81e-03	48	148	3	C0917731
Disease	Male infertility	CDC14A TDRD7 DROSHA	1.81e-03	48	148	3	C0021364
Disease	Subfertility, Male	CDC14A TDRD7 DROSHA	1.81e-03	48	148	3	C0848676
Disease	Familial idiopathic steroid-resistant nephrotic syndrome	MYO1E CD2AP	1.88e-03	13	148	2	cv:C4273714
Disease	developmental disorder of mental health (implicated_via_orthology)	TANC2 RING1 PLXNB1	1.92e-03	49	148	3	DOID:0060037 (implicated_via_orthology)
Disease	Unipolar Depression	CYP2C19 CYP2C9 MAOA NTRK3 GRM1 FREM3	2.01e-03	259	148	6	C0041696
Disease	early cardiac repolarization measurement	SLC9A8 AKR1C8	2.19e-03	14	148	2	EFO_0004885
Disease	polycystic kidney disease (implicated_via_orthology)	IFT172 XYLT2	2.19e-03	14	148	2	DOID:0080322 (implicated_via_orthology)
Disease	Testicular Germ Cell Tumor	HPGDS ALOX5	2.19e-03	14	148	2	C1336708
Disease	Epilepsy	TANC2 GRM1 STX1B PCDH19	2.25e-03	109	148	4	C0014544
Disease	mean reticulocyte volume	SCO2 MYO9B RBL1 ADCY9 PTPRA PTPRN ANTXR1 AFDN PREX1 PRXL2C PCM1	2.39e-03	799	148	11	EFO_0010701
Disease	nervous system disorder	CYP2C8 CYP2C9 CAMKK1	2.41e-03	53	148	3	C0027765
Disease	chenodeoxycholate measurement	CYP2C8 HMCN1	2.51e-03	15	148	2	EFO_0010471
Disease	lysophosphatidylethanolamine 18:0 measurement	ADAMTS16 TNR	2.51e-03	15	148	2	EFO_0010367
Disease	16a-hydroxy DHEA 3-sulfate measurement	CYP2C8 CYP2C9	2.51e-03	15	148	2	EFO_0800301
Disease	Metastatic melanoma	TRIO PDGFRA NEK10	2.54e-03	54	148	3	C0278883
Disease	immature platelet fraction	MYO9B CD2AP PLEC PACSIN2	2.65e-03	114	148	4	EFO_0009187
Disease	ecosanoids measurement	CYP2C8 CYP2C9 CYP2C18	2.68e-03	55	148	3	EFO_0020044
Disease	cathepsin L1 measurement	GRM1 PLXDC2	2.86e-03	16	148	2	EFO_0010619
Disease	andro steroid monosulfate C19H28O6S (1) measurement	CYP2C8 CYP2C9	2.86e-03	16	148	2	EFO_0800305
Disease	Hypertrophic Cardiomyopathy	SCO2 RYR2 KAT8	2.97e-03	57	148	3	C0007194
Disease	immature platelet measurement	MYO9B CD2AP PLEC PACSIN2	3.09e-03	119	148	4	EFO_0803541
Disease	Huntington Disease	MAOA HTT	3.23e-03	17	148	2	C0020179
Disease	lifestyle measurement, maximum cigarettes per day measurement	FREM3 TDRD7 OLFM3 PCNX1	3.38e-03	122	148	4	EFO_0009264, EFO_0010724
Disease	sexual dimorphism measurement	LIN7C MYO9B RBL1 MATN3 STX1B ADCY9 SEPTIN2 SNX32 PAPPA PLEC PC SUCO EPB41L1	3.87e-03	1106	148	13	EFO_0021796
Disease	metabolonic lactone sulfate measurement	CYP2C9 CYP2C18	4.04e-03	19	148	2	EFO_0800659
Disease	Cardiomyopathies	SCO2 CYP2C9 LAMA4 RYR2	4.23e-03	130	148	4	C0878544
Disease	asthma	ERCC4 COL15A1 MYO9B NEK10 SPEF2 CFHR5 RING1 NUDT5 PRKG1 UHRF2	4.72e-03	751	148	10	MONDO_0004979
Disease	in situ carcinoma (is_marker_for)	PDGFRA ALOX5	4.93e-03	21	148	2	DOID:8719 (is_marker_for)
Disease	Nephritis, Tubulointerstitial	CYP2C9 SLC3A1	4.93e-03	21	148	2	C0041349

Protein segments in the cluster

Peptide	Gene	Start	Entry
YSLYEVHVSGERRLD	AFDN	91	P55196
HIDSAYLYQNEEEVG	AKR1C8	51	Q5T2L2
DIEYIRSHYNIEDFI	CFAP61	531	Q8NHU2
HEGFERASEQIYYEN	ANTXR1	121	Q9H6X2
HYRDARITEIYEGTS	ACADS	381	P16219
VEEYVRYQLEHENEP	NT5C1A	76	Q9BXI3
YHIEEGEEVFYQLEG	HAAO	46	P46952
EASRLEQEYVHQVYE	ALKBH8	366	Q96BT7
EQEYVHQVYEEIAGH	ALKBH8	371	Q96BT7
YIYQNEHEVGEAIRE	AKR1D1	56	P51857
VDEYEHYERVENGDF	CDC14A	166	Q9UNH5
PYTDAVVHEIQRYSD	CYP2C8	346	P10632
EVVLSGDDEEYQRIY	AHNAK	111	Q09666
VEYDYDAVHDDELTI	CD2AP	6	Q9Y5K6
EKGEYDLVSAYEVDH	ADAMTS16	56	Q8TE57
DLVSAYEVDHRGDYV	ADAMTS16	61	Q8TE57
LVENVKYEDIYEDRH	TFAP2B	16	Q92481
SEYEQEQGEDELVYH	RBM33	116	Q96EV2
DIIDHYRKEQIVEGY	RASA1	421	P20936
VVSRYGIHEEYNEEH	GPR141	151	Q7Z602
EGDYHVEMEAYDTVR	KLHL30	526	Q0D2K2
PGHEQEEDYRYEVLT	ARIH1	91	Q9Y4X5
RTYTIRNEHVDYVDV	MAOA	51	P21397
RNEHVDYVDVGGAYV	MAOA	56	P21397
YEEGHVYELDVQAKD	PCDH19	306	Q8TAB3
QTEENELEGRHIYIY	PDGFRA	106	P16234
SEDVVRRHYVGELYN	RAB3GAP2	1266	Q9H2M9
EDHGPIYNYRVEISV	CACNA1F	1101	O60840
HDEEYRSEDIHIIYI	VCPKMT	206	Q9H867
IYDTIYAHQDKRDDV	COQ2	246	Q96H96
DYDAEEHVGNYVSEL	EPB41L1	226	Q9H4G0
DEGASLYHVYEVNLV	PTPRN	826	Q16849
ERSNRIVVDEVYDYH	IL18RAP	201	O95256
IVVDEVYDYHQGTYV	IL18RAP	206	O95256
FYHRETEGEEQAQYL	KCNA2	416	P16389
REVYEHVYETVDISS	LIN7C	51	Q9NUP9
QDEHVDYVESYSVIE	MATN1	196	P21941
EPLEEHVFYVETYGV	MATN3	236	O15232
HAIEYISYVTEIHEE	MOV10L1	596	Q9BXT6
EYDEHFPEIIERATY	MAGED4	446	Q96JG8
HIVRIVDVYENLYAG	MAPKAPK2	116	P49137
DEAAYHLIIELYDRG	NEMF	106	O60524
KIIHVEYYQEGEISE	NTRK3	346	Q16288
VVRLAYNESEDRHYA	CAMKK1	141	Q8N5S9
VLEETHYENGEYIIR	PRKG1	236	Q13976
NDQEGREEFYVHYVG	KAT8	81	Q9H7Z6
FGLDVYDQVYHEIID	LIPJ	346	Q5W064
EFVERIHELGYNTYA	FGF3	116	P11487
IFAYLDIQYEDHRIE	HPGDS	21	O60760
ERIRYVIFDEVHYLG	DDX60L	861	Q5H9U9
HGYAVNEDDVARDLY	CPVL	166	Q9H3G5
VHGEEGRVYVYRLSE	ITGAE	541	P38570
NELRELVHYYEQTSD	PCM1	501	Q15154
EYDDPTVLYEAIVSH	PCNX1	1871	Q96RV3
RAEDGTEVAYIEYDV	PLXNB1	346	O43157
EIVANEYLGYGEEQH	NEK10	166	Q6ZWH5
IGHYVRDISAYEELV	NEK10	471	Q6ZWH5
REIHVLDTDYEGYAI	LCN8	101	Q6JVE9
VAEEHLTVDARVYSY	NUDT5	186	Q9UKK9
ESGDALYYRVVRAHE	PEAK3	181	Q6ZS72
EHGYGEEEKVIYRTV	DNAH12	1556	Q6ZR08
YGIQIYTLDEHLEID	PAPPA	851	Q13219
YHRYLQEVIDVLETD	NUCB1	51	Q02818
YSEHRYRIFGETIDI	OSGEP	141	Q9NPF4
YQTRAEEIEHYARQV	NBAS	846	A2RRP1
DDRTHIGYKVYEEIA	HMCN1	176	Q96RW7
AEGRLQEAEYHYLEA	IFT172	1041	Q9UG01
IEYVHGYFSSEQVVD	PROSER1	26	Q86XN7
VRALYDYEGQEHDEL	PACSIN2	431	Q9UNF0
YEELGAVEQHVRYET	FZD8	376	Q9H461
QHYRESYISDELELD	FRMD1	351	Q8N878
EEQYVSDILNYIDHG	HTT	746	P42858
PYTDAVVHEVQRYID	CYP2C19	346	P33261
YVDHYRSLEEDQEPI	ELOA	216	Q14241
YRIEEYNHVLIEETD	ELOA	616	Q14241
HLYVVSYEAAGEIVR	DPP9	526	Q86TI2
YVFQTRKEQYEHADE	BFSP1	6	Q12934
EVSYRLHYHGDVEAD	ADCY9	1001	O60503
EIRKEEYGHNEVVEY	CFHR5	221	Q9BXR6
DIIGDVQIYDDYFIH	ITIH6	256	Q6UXX5
SQRYQVGVHYELTEE	DYNC1H1	1001	Q14204
PYTDAVVHEIQRYID	CYP2C18	346	P33260
PYTDAVVHEVQRYID	CYP2C9	346	P11712
HIETLYELDIEYSQV	FECH	341	P22830
SVNEVPDYHEDIHTY	CCNA2	171	P20248
LQEYVYEHEREGNTE	GRM1	1106	Q13255
GVEDGHQRIILYYTE	COL15A1	126	P39059
YTYAIIVQEVEREDA	SACS	4201	Q9NZJ4
EDQDYIVDHSIAIYL	SCO2	216	O43819
RYVDEAHQYILEFDG	RYR2	2931	Q92736
FDQIVYHLDLVETDY	EPB41L4B	111	Q9H329
GIQEEIGAYDYEELH	OLFM3	186	Q96PB7
IGAYDYEELHQRVLS	OLFM3	191	Q96PB7
YPSREEYEAHQDRVL	RING1	111	Q06587
REIAGEEKRVYYVHD	COL6A6	581	A6NMZ7
HYLYGDTELEVTSLE	PTPRA	501	P18433
IYDAVSGIDTQIIYH	LAMA4	651	Q16363
GDAEYHVNESARYVE	FREM3	2016	P0C091
YEQRYHSGDVRLDTV	PTGFRN	211	Q9P2B2
TDRPTVIEYDDHEYI	DROSHA	586	Q9NRR4
EDQHTVLAYLYEIRT	SPEF2	1051	Q9C093
GEVDRTEFEQYLHFV	SOX17	356	Q9H6I2
EEVVEQYGIDTIRLY	LARS2	651	Q15031
IQIGSEEEVYISHIY	TDRD15	961	B5MCY1
TAEVVDIYYEGDQVV	ALOX5	486	P09917
YEEYVLTVGDFDERI	RBL1	306	P28749
YDEVQEVVYFPAVVH	SCRN3	31	Q0VDG4
DYIIRSHEVKAEGYE	PPP5C	421	P53041
IHEDGYSEEECRQYR	GNAI2	56	P04899
VEVDEHLDYRVGVAF	FSD2	626	A1L4K1
DDPYYDIARHQIVEV	ARHGAP1	61	Q07960
VDNVHLEHGVVYEYV	PREX1	846	Q8TCU6
QIEEDTDHNYYISRI	PLXDC2	106	Q6UX71
SHDQYRELQRYAEEV	NANS	91	Q9NR45
LSELTEEEYEAHYIR	SLC9A8	506	Q9Y2E8
DSHYVVYTRELDGID	SLC3A1	576	Q07837
HEDIYSVQDIFEEEY	TANC2	1401	Q9HCD6
RQRIELTFDEHYYIE	NETO2	81	Q8NC67
HYEKEELEGHRTLYV	SLC4A8	36	Q2Y0W8
IFDEVHYINDVERGV	SKIV2L	421	Q15477
ILYYSVSEERHIAVE	TDRD7	946	Q8NHU6
HYYVESIADLTEGLE	PDXP	281	Q96GD0
IVVHADELEELINYY	CLTC	1276	Q00610
VHYDFVGSYERLEAD	CHST14	291	Q8NCH0
GHRVETEHYEEIEDY	NCAPH	536	Q15003
AEDAYTSRLGYEEHI	CLUH	336	O75153
YPHVEDYRRTVTEID	PSME3	196	P61289
TGYSHEIYVDPEREI	PRXL2C	111	Q7RTV5
YEVEELETATERYLH	RNF31	1021	Q96EP0
VGRDEREDITHTYKY	TGM2	431	P21980
LYAIQDREGSYHEVT	XIRP2	1146	A4UGR9
VAADEDVIYHIQYDE	UHRF2	201	Q96PU4
YYVREAHGIVVTDVA	PREB	336	Q9HCU5
VAERITEDYYVHLIA	TM9SF4	121	Q92544
VFEYHNIRVYDEEAT	SSH2	351	Q76I76
DRIEYNVEHAVDYVE	STX1A	231	Q16623
RIEYNVEHSVDYVER	STX1B	231	P61266
AYEVEYHVLQEELID	TBC1D1	1056	Q86TI0
VVYSTLAGEQYHEVL	TNR	626	Q92752
DFLIYEYRNGHQEVE	SCN3B	71	Q9NY72
IHGVLYYVEHRDDEL	PREPL	296	Q4J6C6
TVDNVHLEYGVVYEY	PREX2	811	Q70Z35
SESVIQEYVDLRTHY	PLEC	1446	Q15149
EYEEIADSQYHSERQ	SUCO	456	Q9UBS9
YINHLVERGDYDIAA	VPS41	401	P49754
YFEAYRHVLEGLQEV	ZNFX1	511	Q9P2E3
YIDEQFERYLHDESG	SEPTIN2	121	Q15019
HEVEPRYVVLYDAEL	ERCC4	571	Q92889
LFENHYEEDYLVIDG	ZCWPW2	316	Q504Y3
HDAYVENEEYAGLII	SNX32	71	Q86XE0
DHEEGYVTFEDVAVY	ZNF419	21	Q96HQ0
VVHSYEELEENYTRA	PC	206	P11498
LDVLEYIHENEYVHG	VRK2	151	Q86Y07
DYLHREVVELAQGYD	XYLT2	271	Q9H1B5
HYVLQELVETERDYV	TRIO	1971	O75962
FRLHEVYIDIYDAQV	ZAN	1986	Q9Y493
EKDHEEYNIGVLDIY	MYO1E	376	Q12965
HVFYYLLLGVSEEER	MYO9B	336	Q13459